Synapse - Surgery

Results (21443)

Long survival in patients with adnexal high-grade serous carcinoma who underwent suboptimal cytoreductive surgery: A whole-genome analysis

Meeting Abstract

Sullivan, M.; Brown, D.; Paula, A. D.; Boerner, T.; O'Cearbhaill, R.; Tew, W.; Grisham, R.; Sonoda, Y.; Leitao, M.; Broach, V.; more...
International Journal of Gynecological Cancer (2024)

Fulltext@MSK | Save

Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas

Meeting Abstract

Rosenbaum, E.; Ehrich, F.; Bradic, M.; Kelly, C. M.; Movva, S.; Chan, J.; Chi, P.; Banks, L.; Dickson, M.; Keohan, M. L.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naïve, advanced gastrointestinal stromal tumor (GIST)

Meeting Abstract

Kelly, C. M.; Bradic, M.; Saunds, S.; Avutu, V.; Chan, J.; D'Angelo, S. P.; Dickson, M.; Gounder, M.; Keohan, M. L.; Movva, S.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

An open label phase IIa study evaluating the preliminary efficacy of intratumoural tigilanol tiglate (TT) in advanced and/or metastatic soft tissue sarcoma (STS)

Meeting Abstract

Bartlett, E. K.; Li, D.; Shemla, S.; Ariyan, C. E.; Dickinson, S.; Crago, A.; Li, G.; Agaram, N.; D'Angelo, S. P.; Maki, R. G.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma

Meeting Abstract

Rosenbaum, E.; Qin, L. X.; Dickson, M.; Movva, S.; Kelly, C. M.; Chan, J.; Chi, P.; Banks, L.; Keohan, M. L.; Gounder, M.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum

Meeting Abstract

Park, W.; O'Connor, C.; Chou, J.; Schwartz, C.; Larsen, M.; Varghese, A.; Yu, K.; Balogun, F.; Yang, J.; Katz, S.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Neoadjuvant nivolumab and nivolumab+ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159

Meeting Abstract

Reuss, J.; Leung, C. H.; Rosner, S.; Zhou, N.; Weissferdt, A.; Pataer, A.; Nassib William, W. Jr; Taube, J.; Broderick, S.; Spicer, J. D.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Longitudinal biomarker analysis and outcomes for patients (pts) treated with neoadjuvant nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma

Meeting Abstract

Burton, E.; Wani, K.; Milton, D.; Lazcano, R.; Tetzlaff, M.; Ross, M. I.; Postow, M. A.; Glitza, I. C.; Wong, M. K. K.; Patel, S.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Phase II multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of HB-200 in patients with detectable TTMV-HPV DNA after definitive treatment for HPV16 + HNSCC

Meeting Abstract

Ho, A. L.; Riaz, N.; Pfister, D.; Wong, R.; Lee, N.; Sherman, E. J.; Haque, S.; Ostrovnaya, I.; Wong, W.
Annals of Oncology (2024)

Fulltext@MSK | Save

Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC)

Meeting Abstract

Dunn, L.; Cracchiolo, J.; Ho, A. L.; Sherman, E. J.; Ganly, I.; Ghossein, R.; Cohen, M.; Wong, W.; Desilets, A.; Michel, L.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save